AD	)	

Award Number: DAMD17-02-1-0261

TITLE: Nuclear Imaging for Assessment of Prostate Cancer Gene Therapy

PRINCIPAL INVESTIGATOR: Dongfeng Pan, Ph.D.

CONTRACTING ORGANIZATION: University of Virginia

Charlottesville, VA 22904

REPORT DATE: April 2005

TYPE OF REPORT: Annual

20060207 019

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

Form Approved OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OME ported purpler. PLASSED ON NOT PET LIPPLY VALUE SORPH TO THE ARQUE ADDRESS.

valid OMB control number. PLEASE DO NOT RET		
1. REPORT DATE	2. REPORT TYPE	3. DATES COVERED
01-04-2005	Annual	12 Mar 2004 – 11 Mar 2005
		5a. CONTRACT NUMBER
4. TITLE AND SUBTITLE		5a. CONTRACT NUMBER
Nuclear Impains for Appagance	nt of Proptoto Concer Cone Thereny	5b. GRANT NUMBER
Nuclear imaging for Assessmen	nt of Prostate Cancer Gene Therapy	
		DAMD17-02-1-0261
		5c. PROGRAM ELEMENT NUMBER
6. AUTHOR(S)		5d. PROJECT NUMBER
Dongfeng Pan, Ph.D.		5e. TASK NUMBER
,		
	•	EC MODICUMENTAL MANAGED
		5f. WORK UNIT NUMBER
7. PERFORMING ORGANIZATION NA	AME(S) AND ADDRESS(ES)	8. PERFORMING ORGANIZATION REPORT
7. PERFORMING ORGANIZATION IN	AWE(3) AND ADDRESS(LS)	
		NUMBER
University of Virginia		
Charlottesville, VA 22904		
Chanottesville, VA 22504		
9. SPONSORING / MONITORING AG	ENCY NAME(S) AND ADDRESS(ES)	10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research a		
		·
Fort Detrick, Maryland 21702-	5012	
		11 SPONSOR/MONITOR'S REPORT
		11. SPONSOR/MONITOR'S REPORT
		11. SPONSOR/MONITOR'S REPORT NUMBER(S)
AS DISTRIBUTION (AVAILABILITY)		
12. DISTRIBUTION / AVAILABILITY S	STATEMENT	
12. DISTRIBUTION / AVAILABILITY S Approved for Public Release; E	STATEMENT	
	STATEMENT	
Approved for Public Release; [	STATEMENT	
	STATEMENT	NUMBER(S)
Approved for Public Release; [	STATEMENT	
Approved for Public Release; [	STATEMENT	NUMBER(S)
Approved for Public Release; E	STATEMENT	NUMBER(S)
Approved for Public Release; [	STATEMENT	NUMBER(S)
Approved for Public Release; E  13. SUPPLEMENTARY NOTES  14. ABSTRACT	STATEMENT Distribution Unlimited	NUMBER(S)
Approved for Public Release; E  13. SUPPLEMENTARY NOTES  14. ABSTRACT  Background: Combination of the cyt	STATEMENT  Distribution Unlimited  totoxic viral thymidine kinase (tk) and the prodrug, acy	NUMBER(S)
Approved for Public Release; E  13. SUPPLEMENTARY NOTES  14. ABSTRACT  Background: Combination of the cyt	STATEMENT  Distribution Unlimited  totoxic viral thymidine kinase (tk) and the prodrug, acy	NUMBER(S)
Approved for Public Release; E  13. SUPPLEMENTARY NOTES  14. ABSTRACT  Background: Combination of the cyt the C4-2 tumor, a subline of LNCaP.	STATEMENT  Distribution Unlimited  totoxic viral thymidine kinase (tk) and the prodrug, acy  . However, it remains unsolved to non-invasively detec	volovir (ACV) has been reported to inhibit the growth of cet the in vivo distribution, expression and persistence of
Approved for Public Release; E  13. SUPPLEMENTARY NOTES  14. ABSTRACT  Background: Combination of the cyt the C4-2 tumor, a subline of LNCaP the toxic gene as well as to evalua	STATEMENT  Distribution Unlimited  totoxic viral thymidine kinase (tk) and the prodrug, acy  However, it remains unsolved to non-invasively detected the therapeutic effect. In this project, we will defended	NUMBER(S)
Approved for Public Release; E  13. SUPPLEMENTARY NOTES  14. ABSTRACT  Background: Combination of the cyt the C4-2 tumor, a subline of LNCaP, the toxic gene as well as to evalua cytotoxic gene therapy study for pro-	STATEMENT  Distribution Unlimited  totoxic viral thymidine kinase (tk) and the prodrug, acy  . However, it remains unsolved to non-invasively detect ate the therapeutic effect. In this project, we will destate cancer.	volovir (ACV) has been reported to inhibit the growth of cit the in vivo distribution, expression and persistence of levelop a nuclear gene imaging approach to assist the
Approved for Public Release; E  13. SUPPLEMENTARY NOTES  14. ABSTRACT  Background: Combination of the cyt the C4-2 tumor, a subline of LNCaP, the toxic gene as well as to evalual cytotoxic gene therapy study for pro Objective/Hypothesis: The distribution	STATEMENT  Distribution Unlimited  totoxic viral thymidine kinase (tk) and the prodrug, acy  . However, it remains unsolved to non-invasively detected the therapeutic effect. In this project, we will destate cancer.  on, expression, and persistence of the prostate specifications.	relovir (ACV) has been reported to inhibit the growth of et the in vivo distribution, expression and persistence of levelop a nuclear gene imaging approach to assist the c Ad-PSA-tk in the C4-2 tumor xenograft model will be
Approved for Public Release; E  13. SUPPLEMENTARY NOTES  14. ABSTRACT  Background: Combination of the cyt the C4-2 tumor, a subline of LNCaP, the toxic gene as well as to evalual cytotoxic gene therapy study for pro Objective/Hypothesis: The distribution	STATEMENT  Distribution Unlimited  totoxic viral thymidine kinase (tk) and the prodrug, acy  . However, it remains unsolved to non-invasively detect ate the therapeutic effect. In this project, we will destate cancer.	relovir (ACV) has been reported to inhibit the growth of et the in vivo distribution, expression and persistence of levelop a nuclear gene imaging approach to assist the c Ad-PSA-tk in the C4-2 tumor xenograft model will be
Approved for Public Release; E  13. SUPPLEMENTARY NOTES  14. ABSTRACT  Background: Combination of the cyt the C4-2 tumor, a subline of LNCaP, the toxic gene as well as to evalual cytotoxic gene therapy study for pro Objective/Hypothesis: The distribution non-invasively and repeatedly determined.	STATEMENT  Distribution Unlimited  totoxic viral thymidine kinase (tk) and the prodrug, acy  However, it remains unsolved to non-invasively detected the therapeutic effect. In this project, we will destate cancer.  The propression, and persistence of the prostate specification of the prostate specification of the prostate specification.	relovir (ACV) has been reported to inhibit the growth of et the in vivo distribution, expression and persistence of levelop a nuclear gene imaging approach to assist the c Ad-PSA-tk in the C4-2 tumor xenograft model will be with a SPECT imaging modality.
Approved for Public Release; E  13. SUPPLEMENTARY NOTES  14. ABSTRACT  Background: Combination of the cyt the C4-2 tumor, a subline of LNCaP, the toxic gene as well as to evalual cytotoxic gene therapy study for pro Objective/Hypothesis: The distribution non-invasively and repeatedly determ Specific Aim of the first year: To syn	STATEMENT Distribution Unlimited  totoxic viral thymidine kinase (tk) and the prodrug, acy . However, it remains unsolved to non-invasively detected the therapeutic effect. In this project, we will destate cancer.  on, expression, and persistence of the prostate specification	relovir (ACV) has been reported to inhibit the growth of et the in vivo distribution, expression and persistence of levelop a nuclear gene imaging approach to assist the ec Ad-PSA-tk in the C4-2 tumor xenograft model will be with a SPECT imaging modality.
Approved for Public Release; E  13. SUPPLEMENTARY NOTES  14. ABSTRACT  Background: Combination of the cyt the C4-2 tumor, a subline of LNCaP, the toxic gene as well as to evalual cytotoxic gene therapy study for pro Objective/Hypothesis: The distribution non-invasively and repeatedly determ Specific Aim of the first year: To symmercaptoethyl)ethylenediaminato][To	STATEMENT Distribution Unlimited  totoxic viral thymidine kinase (tk) and the prodrug, acy . However, it remains unsolved to non-invasively detected the therapeutic effect. In this project, we will destate cancer.  on, expression, and persistence of the prostate specification	relovir (ACV) has been reported to inhibit the growth of et the in vivo distribution, expression and persistence of levelop a nuclear gene imaging approach to assist the cc Ad-PSA-tk in the C4-2 tumor xenograft model will be with a SPECT imaging modality. p-5-{3-oxo[N,N-bis(2-tection using a small animal gamma detector.
Approved for Public Release; E  13. SUPPLEMENTARY NOTES  14. ABSTRACT  Background: Combination of the cyt the C4-2 tumor, a subline of LNCaP, the toxic gene as well as to evalua cytotoxic gene therapy study for pro Objective/Hypothesis: The distribution non-invasively and repeatedly determ Specific Aim of the first year: To symercaptoethyl)ethylenediaminato][To Progress and outcome: In last report	STATEMENT Distribution Unlimited  totoxic viral thymidine kinase (tk) and the prodrug, acy . However, it remains unsolved to non-invasively detected the therapeutic effect. In this project, we will destate cancer.  on, expression, and persistence of the prostate specification of the prostate specification of the vivo by tracing the radiolabeled TK substrates in the size a radiolabeled TK substrate, 2'-Deoxy-2'fluoroc-99m] technetium(V)-1(E)-propenyl}uridine, for TK detact of 2003 which covers from September of 2002 to Marketic states.	relovir (ACV) has been reported to inhibit the growth of extitute in vivo distribution, expression and persistence of levelop a nuclear gene imaging approach to assist the cc Ad-PSA-tk in the C4-2 tumor xenograft model will be with a SPECT imaging modality. 0-5-{3-oxo[N,N-bis(2-tection using a small animal gamma detector. arch of 2003, we reported our efforts to synthesize
Approved for Public Release; E  13. SUPPLEMENTARY NOTES  14. ABSTRACT  Background: Combination of the cyt the C4-2 tumor, a subline of LNCaP, the toxic gene as well as to evalua cytotoxic gene therapy study for pro Objective/Hypothesis: The distribution non-invasively and repeatedly determ Specific Aim of the first year: To symercaptoethyl)ethylenediaminato][To Progress and outcome: In last report	STATEMENT Distribution Unlimited  totoxic viral thymidine kinase (tk) and the prodrug, acy . However, it remains unsolved to non-invasively detected the therapeutic effect. In this project, we will destate cancer.  on, expression, and persistence of the prostate specification	relovir (ACV) has been reported to inhibit the growth of extitute in vivo distribution, expression and persistence of levelop a nuclear gene imaging approach to assist the cc Ad-PSA-tk in the C4-2 tumor xenograft model will be with a SPECT imaging modality. 0-5-{3-oxo[N,N-bis(2-tection using a small animal gamma detector. arch of 2003, we reported our efforts to synthesize
Approved for Public Release; E  13. SUPPLEMENTARY NOTES  14. ABSTRACT  Background: Combination of the cyt the C4-2 tumor, a subline of LNCaP, the toxic gene as well as to evalua cytotoxic gene therapy study for pro Objective/Hypothesis: The distribution non-invasively and repeatedly determ Specific Aim of the first year: To symmercaptoethyl)ethylenediaminato][To Progress and outcome: In last report fragments A and B. In this report w	STATEMENT Distribution Unlimited  totoxic viral thymidine kinase (tk) and the prodrug, acy . However, it remains unsolved to non-invasively detected the therapeutic effect. In this project, we will destate cancer.  on, expression, and persistence of the prostate specification	relovir (ACV) has been reported to inhibit the growth of ext the in vivo distribution, expression and persistence of levelop a nuclear gene imaging approach to assist the cc Ad-PSA-tk in the C4-2 tumor xenograft model will be with a SPECT imaging modality. b-5-{3-oxo[N,N-bis(2-tection using a small animal gamma detector. arch of 2003, we reported our efforts to synthesize rothymidine. We will characterize the structure of the
Approved for Public Release; E  13. SUPPLEMENTARY NOTES  14. ABSTRACT  Background: Combination of the cyt the C4-2 tumor, a subline of LNCaP, the toxic gene as well as to evalua cytotoxic gene therapy study for pro Objective/Hypothesis: The distribution non-invasively and repeatedly determ Specific Aim of the first year: To symercaptoethyl)ethylenediaminato][To Progress and outcome: In last report fragments A and B. In this report w final tracer and test the pharmacoking the supplements of the supplement of the supplements of the supplement of the	STATEMENT Distribution Unlimited  totoxic viral thymidine kinase (tk) and the prodrug, acy . However, it remains unsolved to non-invasively detected the therapeutic effect. In this project, we will destate cancer.  on, expression, and persistence of the prostate specification in vivo by tracing the radiolabeled TK substrates in the size a radiolabeled TK substrate, 2'-Deoxy-2'fluoroco-99m] technetium(V)-1(E)-propenyl}uridine, for TK defined to f 2003 which covers from September of 2002 to Mare successfully linked the radiometal chelator with fluor metics and pharmacodynamics of the tracer in next reservable.	relovir (ACV) has been reported to inhibit the growth of control to the invivo distribution, expression and persistence of levelop a nuclear gene imaging approach to assist the control to a second t
Approved for Public Release; E  13. SUPPLEMENTARY NOTES  14. ABSTRACT  Background: Combination of the cyt the C4-2 tumor, a subline of LNCaP, the toxic gene as well as to evalua cytotoxic gene therapy study for pro Objective/Hypothesis: The distribution non-invasively and repeatedly determ Specific Aim of the first year: To symmercaptoethyl)ethylenediaminatol[To Progress and outcome: In last report fragments A and B. In this report w final tracer and test the pharmacoking genes of tk and luciferase were considered.	STATEMENT Distribution Unlimited  totoxic viral thymidine kinase (tk) and the prodrug, acy . However, it remains unsolved to non-invasively detected the therapeutic effect. In this project, we will destate cancer.  on, expression, and persistence of the prostate specification	relovir (ACV) has been reported to inhibit the growth of control to the invivo distribution, expression and persistence of levelop a nuclear gene imaging approach to assist the control to a second t

#### 15. SUBJECT TERMS

prostate cancer, gene therapy, imaging

16. SECURITY C	LASSIFICATION OF:		17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE		_	19b. TELEPHONE NUMBER (include area
	Ĭ		טט	7	

## **Table of Contents**

Cover	1
SF 298	2
Table of Contents	3
Introduction	4
Body	4
Key Research Accomplishments	6
Reportable Outcomes	7
Conclusions	7
References	7
Appendices	none

#### Introduction

The objective of this project is to develop a noninvasive imaging assay using single photon emission computed tomography (SPECT) for assessment of gene therapeutic efficacy and diagnosis of metastasis of prostate cancer.

Currently, nuclear imaging technology has demonstrated the greatest potential to non-invasively image gene activity in animals and humans due to its high sensitivity. By replacing the acyclovir (ACV) with a radioactive analogue, it is possible to non-invasively and repeatedly monitor the *in vivo* distribution of the transduced tk construct. It may assist in determining the optimal timing for ACV administration, confirming the cytotoxic sites, and assessing the therapeutic efficacy. Further refinement of this technology could also provide a non-invasive approach to identify any metastasis sites in a clinical setting.

In the original plan, we proposed to synthesize a novel thymidine kinase (TK) substrate, I-123 labeled 1-(2-deoxy-2-fluoro-β-D-ribofuranosyl)-

5(E)-(2-iodovinyl)uracil (IVFRU). However, the recent progress of Tc-99m chemistry that Tc-99m labeled radiopharmaceuticals, such as TRODAT, being able to penetrate lipid membrane raises our interest to synthesize a Tc-99m labeled TK substrate for gene imaging, because of the nearly optimal nuclear properties of Tc-99m, as well as its convenient and low cost production by means of commercial generator columns. As a result, we modified our plan by switching the target molecule, [I-123]IVFRU with 2'-Deoxy-2'fluoro-5-{3-oxo[N,N-bis(2-mercaptoethyl)ethylenediaminato][Tc-99m] technetium(V)-1(E)-propenyl}uridine.

In biological experiment, we constructed prostate specific adenovirus vector, Ad-PSA-TK. To test the target specificity of PSA promoter, viral vector Ad-PSA-Luc was constructed and a charge coupled device (CCD) video camera was used to image noninvasively human prostate tumors and metastases in nude mice after injection of  $2\times10^9$  PFU of Ad-PSA-Luc virus via tail vein.

### **Body**

#### 1. Chemistry

The target molecule, 2'-Deoxy-2'fluoro-5-{3-oxo[N,N-bis(2-mercaptoethyl)ethylenediaminato][Tc-99m] technetium(V)-1(E)-propenyl}uridine 12, was convergently synthesized from synthons 5 and 8. The detail of the synthesis was reported in *Tetrahedron Letters*, 2004, 45, 8673-8676.

Briefly, the synthesis of 5-(5-bromopent-1(E)-enyl)-1-(3,5-diacetyl-2-fluoro-2-deoxy-1- $\beta$ -D-ribofuranosyl)uracil **5** and N,N'-bis-[2-(4-methoxybenzylsulfanyl)ethyl]ethylenediamine **8** are outlined in scheme 2 and 3.

Scheme 3. Reagents: (i) CeOH, molecular sieve (4Å), DMF.

7

6

Coupling of thymidine analog 5 and chelator fragment 8 produces 9. The removal of acetyl protecting groups of 9 with potassium carbonate in aqueous methanol yields 10.

PMB = p-methoxylbenzyl

The thiol protecting groups, 4-methoxybenzyl, of **10** are removed with Hg(OAc)<sub>2</sub> in TFA to give trifluoroacetate salts of **11**. The crude air-sensitive compound **11** is conjugated with technetium immediately, without purification. Addition of [<sup>99m</sup>Tc]pertechnetate in PBS into the aqueous methanol of the crude **11** in the presence of Sn-glucoheptonate in 80°C water bath for 30 min and thereafter HPLC purification yields the target compound, FTcAU **12** with radiochemical yield of 42%. To characterize the chemical structure of the FTcAU **12**, its analog of rhenium-188 conjugate, FReAU **13**, is synthesized with modifying a similar reaction condition by adding tetrabutylammonium tetrachlorooxorhenate(V) into a solution of compound **11** in methanol and stirring for 12 hours. The rhenium conjugate **13** is purified by flash chromotography and its chemical structure is characterized with <sup>1</sup>HNMR and high resolution ESI-MS. The characterization of FTcAU is carried out using reverse phase HPLC by co-injection with FReAU (schem **4**).

Reagents: (i) DIEA, CH3CN; (ii) K2CO3; (iii) Hg(OAc)2/TFA, H2S; (iv) [99mTc]NaTcO4, Sn-gluceptate (v) (Bu4N)+(ReOCI4)-.

Scheme 4

#### 2. Biology

In summary, we demonstrated that the AdPSA-Luc can generate high level expression of luciferase gene under the control of the 5837 bp long PSA promoter in

lungs of normal mice via tail vein injection. To our knowledge, this is the first report that unequivocally demonstrates specific gene expression in lung tissue elicited by a PSA promoter. This may predict PSA expression in lungs of normal mice. These results indicate the potential limitations of the suicide gene therapy of prostate cancer based on the selectivity of PSA promoter. By contrary, it has encouraging implications for the further development of vectors via PSA to enable gene therapy for pulmonary vascular diseases. Viral Vector

### **Key Research Accomplishments:**

Chemistry: The Tc-99m labeled potential imaging tracer, 2'-Deoxy-2'fluoro-5-{3-oxo[N,N-bis(2-mercaptoethyl)ethylenediaminato][Tc-99m] technetium(V)-1(E)-propenyl}uridine, was successfully synthesized.

*Biology:* Normal lung tissue of nude mice demonstrates specific gene expression elicited by a PSA promoter.

## **Reportable Outcomes:**

*Chemistry*: Synthesis of a potential Tc-99m labeled TK substrate was published in *Tetrahedron Letters*;

Biology: Highly specific expression of luciferase gene in lungs of naïve nude mice directed by prostate-specific antigen promoter was reported in *Biochemical and Biophysical Research Communications*.

#### **Conclusions:**

- 1. We have obtained a Tc-99m labeled thymidine analog and evaluation of its activity as TK substrate is undergoing.
- 2. Highly specific gene expression in lung tissue elicited by a PSA promoter predicts PSA expression in lungs of normal mice.

#### Reference:

- 1. Synthesis of a novel Tc-99m labeled TK repot probe, 2'-Deoxy-2'fluoro-5-{3-oxo[*N*,*N*-bis(2-mercaptoethyl)ethylenediaminato][Tc-99m] technetium(V)-1(*E*)-propenyl}uridine, Y, Zhang, X. Dai, D. Kallmes and D. Pan, *Tetrahedron Letters*, 2004, 45, 8673-8676.
- 2. Highly specific expression of luciferase gene in lungs of naïve nude mice directed by prostate-specific antigen promoter, H. Li, J. Li, G. Helm and D. Pan, *Biochemical and Biophysical Research Communications*, 2005, 334(4), 1287-1291.
- 3. Highly Specific Expression of the Luciferase Gene in Lungs of Naïve Nude Mice Directed by Prostate Specific Antigen Promoter, Hongwei Li, Jin Zhong Li, Gregory A. Helm, Dongfeng Pan, *The 8<sup>th</sup> Annual Meeting of the American Society of Gene Therapy*, June 1-5, 2005, St. Louis, MO.